E
Ensoma
Innovative in vivo treatments using DNA editing to engineer immune cells for curative therapies
About Ensoma
Ensoma operates in the biotechnology sector, focusing on developing advanced in vivo treatments that utilize DNA editing to engineer immune cells for curative therapies. The company serves healthcare providers and patients, particularly those suffering from diseases that can be treated through genetic engineering of the hematopoietic system. Ensoma's business model revolves around leveraging its proprietary technology platform, Engenious, which combines innovative delivery mechanisms with a comprehensive DNA editing toolkit. This allows for precise engineering of immune cells, offering a one-time treatment solution that aims to cure diseases from within the body. Ensoma generates revenue through partnerships with healthcare institutions and top-tier investors who support its bold vision of pioneering a new kind of medicine. The company operates primarily in the United States but has a global outlook, aiming to transform the landscape of curative therapies through its cutting-edge technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Boston, United States
- Employees
- 53
- Open positions
- None listed
- Dealroom signal
- 61.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Jan 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2025 | $53M | $425M | 5AM Ventures · Delos Capital · F-Prime · Bill & Melinda Gates Foundation | ↗ |
| SERIES BOther financing | May 2023 | $50M | $425M | SymBiosis · Bioluminescence Ventures · Kite Pharma · Delos Capital | ↗ |
Growth signals
Latest recorded traffic for Ensoma is 4.6K monthly website visits, up 4.5% over the last three months. Ensoma's team declined 33.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A21 investors entered at this stage
5AM Ventures
Takeda Ventures
F-Prime
Alexandria Venture Investments- CCCormorant Capital
Hans-Peter Kiem
RIT Capital Partners
Viking Global Investors
SymBiosis
André Lieber
Arix Bioscience
Bill & Melinda Gates Foundation
Cormorant Asset Management
Fred Hutchinson Cancer Research Center
Qatar Investment Authority
Solasta Ventures
Catalio Capital Management
Mirae Asset
Bioluminescence Ventures
Kite Pharma
Delos Capital
Series B and later4 investors entered at this stage
Gilead Sciences
Hanwha
Mirae Asset Capital
RTW Investments
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ensoma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ensoma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.